Pricing Log in Create free account
Friday 6 November 2026 Export AUPH’s income statement to Excel — free account

Aurinia Pharmaceuticals Inc

AUPH Healthcare Biotechnology

Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024.

Revenue
+13.9%
EPS
0.00%
Free cash flow
+4.41%
Total debt
−30.0%

Quarter to September 2026, against a year earlier

16.30 0.09 +0.56%
Market cap
$2.2B
P/E
6.8×
Fwd P/E
17.6×
Dividend yield
—
F-score
8/9
Altman Z
7.86
Beneish M
−0.88
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Aurinia Pharmaceuticals Inc (AUPH) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Aurinia Pharmaceuticals Inc (AUPH) trades at a EV/EBITDA of 10.5×. Over the past ten years it has ranged from 0.0× (December 2024) to 94.6× (December 2024); the current reading is higher than 86% of that period. That is above the Biotechnology industry median of 0.7× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 13.4× (85.81%)
FY2024 94.6× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 10.5× (7.20%)
Jun 2026 11.3× 3.41%
Mar 2026 10.9× (18.60%)
Dec 2025 13.4× 15.17%
43 more quarters

Against its own ten years

Low 0.0× High 94.6×
Ten-year median 0.0×
Current reading's percentile 86

EV/EBITDA against peers

Company EV/EBITDA
PVLA Palvella Therapeutics, Inc. compare n/m
BHVN Biohaven Ltd. compare n/m
VERA Vera Therapeutics, Inc. compare n/m
CLDX Celldex Therapeutics, Inc. compare n/m
IMNM Immunome, Inc. compare n/m
LKFT Lakefront Biotherapeutics - Sponsored ADR compare 0.9×
AUPH Aurinia Pharmaceuticals Inc 10.5×
ADMA ADMA Biologics Inc compare 13.0×
VCEL Vericel Corporation compare 79.1×
Biotechnology industry median 0.7×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on AUPH